EWNYSEOrthopedic, Prosthetic & Surgical Appliances & SuppliesFiscal year ends December 31
Edwards Lifesciences Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$87.22+0.62 (+0.72%)
Close on Oct 19, 2026
- Market cap
- $50.38B
- P/E (TTM)
- 50.1
- Dividend yield
- –
Edwards Lifesciences statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Orthopedic, Prosthetic & Surgical Appliances & Supplies companies for comparison
Valuation
| Measure | Edwards Lifesciences | Industry median |
|---|---|---|
| Market Cap | $50.27B | $229.23M |
| Enterprise Value | $46.73B | $194.73M |
| PE Ratio | 50.13 | 33.41 |
| PS Ratio | 7.72 | 3.14 |
| PB Ratio | 4.73 | 3.19 |
| P/TBV Ratio | 6.90 | 4.69 |
| P/FCF Ratio | 35.07 | 27.25 |
| P/OCF Ratio | 29.22 | 22.23 |
Enterprise value
| Measure | Edwards Lifesciences | Industry median |
|---|---|---|
| EV / Sales | 7.18 | 2.93 |
| EV / EBITDA | 28.94 | 19.97 |
| EV / EBIT | 32.25 | 25.47 |
| EV / FCF | 32.59 | 27.85 |
Income (trailing twelve months)
| Measure | Edwards Lifesciences | Industry median |
|---|---|---|
| Revenue | $6.51B | $102.39M |
| Gross Profit | $5.07B | $60.36M |
| Operating Income | $1.45B | -$4.31M |
| Pretax Income | $1.42B | -$2.26M |
| Net Income | $1.00B | -$6.57M |
| EBITDA | $1.61B | -$1.98M |
| EPS (Diluted) | $1.74 | -$0.07 |
Margins
| Measure | Edwards Lifesciences | Industry median |
|---|---|---|
| Gross Margin | 77.8% | 55.1% |
| Operating Margin | 22.3% | -6.04% |
| Pretax Margin | 21.8% | -4.11% |
| Profit Margin | 15.4% | -10.5% |
| EBITDA Margin | 24.8% | -2.67% |
| FCF Margin | 22.0% | -0.30% |
Returns
| Measure | Edwards Lifesciences | Industry median |
|---|---|---|
| Return on Equity (ROE) | 9.50% | -19.2% |
| Return on Assets (ROA) | 7.35% | -13.3% |
| Return on Invested Capital (ROIC) | 14.3% | -4.11% |
| Return on Capital Employed (ROCE) | 11.7% | -9.07% |
Growth
| Measure | Edwards Lifesciences | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 14.6% | 8.85% |
| Net Income Growth (YoY) | -75.8% | 10.6% |
| EPS Growth (YoY) | -75.0% | 10.6% |
| FCF Growth (YoY) | 143.9% | 10.6% |
| Revenue Growth (3Y CAGR) | 10.8% | 7.08% |
| Revenue Growth (5Y CAGR) | 6.70% | 11.8% |
| EPS Growth (3Y CAGR) | -9.14% | 3.06% |
| EPS Growth (5Y CAGR) | 7.08% | 7.64% |
Balance sheet
| Measure | Edwards Lifesciences | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $4.25B | $37.33M |
| Total Debt | $598.70M | $72.66M |
| Net Cash (Debt) | $3.65B | $3.92M |
| Net Cash Per Share | $6.34 | $0.28 |
| Equity (Book Value) | $10.62B | $57.36M |
| Book Value Per Share | $18.42 | $2.81 |
| Tangible Book Value | $7.28B | $10.71M |
| Working Capital | $5.31B | $54.64M |
Financial position
| Measure | Edwards Lifesciences | Industry median |
|---|---|---|
| Current Ratio | 4.52 | 2.50 |
| Quick Ratio | 3.33 | 1.54 |
| Debt / Equity | 0.06 | 0.38 |
| Debt / EBITDA | 0.37 | 2.31 |
| Debt / FCF | 0.42 | 3.50 |
| Net Debt / EBITDA | -2.26 | 1.53 |
Cash flow (trailing twelve months)
| Measure | Edwards Lifesciences | Industry median |
|---|---|---|
| Operating Cash Flow | $1.72B | -$653.46K |
| Capital Expenditures | -$286.70M | -$3.69M |
| Free Cash Flow | $1.43B | -$835.02K |
| FCF Per Share | $2.49 | -$0.02 |
Efficiency
| Measure | Edwards Lifesciences | Industry median |
|---|---|---|
| Asset Turnover | 0.48 | 0.59 |
| Inventory Turnover | 1.27 | 2.21 |
| Revenue Per Employee | $407.02K | $322.75K |
| Profits Per Employee | $62.81K | -$52.11K |
| Employee Count | 16,000 | 197 |
Dividends and yields
| Measure | Edwards Lifesciences | Industry median |
|---|---|---|
| Earnings Yield | 2.00% | -6.92% |
| FCF Yield | 2.85% | -0.62% |
| Buyback Yield | 2.40% | 0.78% |
| Shareholder Yield | 2.40% | 0.84% |
Shares
| Measure | Edwards Lifesciences | Industry median |
|---|---|---|
| Shares Outstanding | 576,400,000 | 44,856,700 |
| Shares Change (YoY) | -1.64% | 3.35% |
| Shares Change (QoQ) | -0.07% | 0.27% |
| Float | 575,114,000 | 36,934,400 |
| Shares Held by Insiders | 0.22% | 10.6% |
| Shares Held by Institutions | 91.0% | 63.5% |
Taxes
| Measure | Edwards Lifesciences | Industry median |
|---|---|---|
| Income Tax | $439.00M | $1.52M |
| Effective Tax Rate | 31.0% | 18.6% |
Scores
| Measure | Edwards Lifesciences | Industry median |
|---|---|---|
| Graham Number | $26.86 | $34.37 |
| Graham Upside | -69.2% | -58.3% |
| Altman Z-Score | 12.37 | 1.95 |
| Piotroski F-Score | 5 | 5 |
| Beneish M-Score | -2.62 | -2.64 |
Calculated by StockData from Edwards Lifesciences's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.